Suppr超能文献

静脉注射和腹腔内给药后持续非卧床腹膜透析患者的替考拉宁药代动力学

Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.

作者信息

Guay D R, Awni W M, Halstenson C E, Kenny M T, Keane W F, Matzke G R

机构信息

Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis, Minnesota.

出版信息

Antimicrob Agents Chemother. 1989 Nov;33(11):2012-5. doi: 10.1128/AAC.33.11.2012.

Abstract

The pharmacokinetics of teicoplanin after single 6-mg/kg intravenous and intraperitoneal doses were studied in five noninfected patients undergoing continuous ambulatory peritoneal dialysis. Biological samples were assayed for teicoplanin content by a microbiological assay technique. Terminal disposition half-life (266.4 +/- 51.9 h [mean +/- standard error of the mean]) was prolonged and total body clearance (0.040 +/- 0.004 ml/min per kg) was reduced compared with values previously reported in subjects with normal renal function. The volume of distribution at steady state (1.15 +/- 0.19 liters/kg) was higher than values previously reported in subjects with normal renal function (0.56 to 0.72 liter/kg). Peritoneal dialysis clearance (0.007 +/- 0.001 ml/min per kg) accounted for only 16.1% of total body clearance. The absolute systemic bioavailability of teicoplanin after intraperitoneal administration was 81.5 +/- 10.7%.

摘要

在5例接受持续性非卧床腹膜透析的未感染患者中,研究了单次静脉注射和腹腔注射6mg/kg替考拉宁后的药代动力学。采用微生物测定技术测定生物样品中的替考拉宁含量。与先前报道的肾功能正常受试者的值相比,终末处置半衰期(266.4±51.9小时[平均值±平均标准误差])延长,全身清除率(0.040±0.004ml/分钟/千克)降低。稳态分布容积(1.15±0.19升/千克)高于先前报道的肾功能正常受试者的值(0.56至0.72升/千克)。腹膜透析清除率(0.007±0.001ml/分钟/千克)仅占全身清除率的16.1%。腹腔给药后替考拉宁的绝对系统生物利用度为81.5±10.7%。

相似文献

2
Teicoplanin pharmacokinetics and bioavailability during peritoneal dialysis.
Clin Pharmacol Ther. 1989 Jun;45(6):674-81. doi: 10.1038/clpt.1989.89.
4
Pharmacokinetics of a single intravenous dose of teicoplanin in subjects with various degrees of renal impairment.
J Antimicrob Chemother. 1988 Jan;21 Suppl A:29-37. doi: 10.1093/jac/21.suppl_a.29.
5
Clinical pharmacokinetics of teicoplanin.
Clin Pharmacokinet. 1990 Mar;18(3):184-209. doi: 10.2165/00003088-199018030-00002.
7
Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis.
J Antimicrob Chemother. 1988 Jan;21 Suppl A:133-9. doi: 10.1093/jac/21.suppl_a.133.
8
Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.
Eur J Clin Pharmacol. 1986;31(4):501-4. doi: 10.1007/BF00613532.
9
Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.
Antimicrob Agents Chemother. 1986 Jul;30(1):15-9. doi: 10.1128/AAC.30.1.15.

引用本文的文献

1
Pharmacokinetics and Target Attainment of Teicoplanin: A Systematic Review.
Clin Pharmacokinet. 2025 Apr;64(4):467-509. doi: 10.1007/s40262-025-01483-7. Epub 2025 Mar 10.
2
Pharmacokinetics in Critically Ill Children with Acute Kidney Injury.
Paediatr Drugs. 2023 Jul;25(4):425-442. doi: 10.1007/s40272-023-00572-z. Epub 2023 Jun 2.
5
Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis.
Antimicrob Agents Chemother. 2012 Jul;56(7):3992-5. doi: 10.1128/AAC.00126-12. Epub 2012 May 7.

本文引用的文献

1
Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp.
Antimicrob Agents Chemother. 1984 Dec;26(6):917-23. doi: 10.1128/AAC.26.6.917.
2
In vitro activity and human pharmacokinetics of teicoplanin.
Antimicrob Agents Chemother. 1984 Dec;26(6):881-6. doi: 10.1128/AAC.26.6.881.
3
Pharmacokinetics of teicoplanin in man after intravenous administration.
J Pharmacokinet Biopharm. 1984 Apr;12(2):119-28. doi: 10.1007/BF01059273.
4
Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.
Clin Pharmacokinet. 1985 Sep-Oct;10(5):404-25. doi: 10.2165/00003088-198510050-00003.
5
Clinical pharmacokinetics of vancomycin.
Clin Pharmacokinet. 1986 Jul-Aug;11(4):257-82. doi: 10.2165/00003088-198611040-00001.
6
Septicaemia due to gram-positive cocci in cancer patients.
J Antimicrob Chemother. 1988 Apr;21 Suppl C:157-65. doi: 10.1093/jac/21.suppl_c.157.
8
Pharmacokinetics of teicoplanin in pediatric patients.
Antimicrob Agents Chemother. 1988 Aug;32(8):1223-6. doi: 10.1128/AAC.32.8.1223.
9
The effect of anaerobiosis on antistaphylococcal antibiotics.
Orthopedics. 1988 Sep;11(9):1285-9. doi: 10.3928/0147-7447-19880901-10.
10
Pharmacokinetics of teicoplanin.
Chemotherapy. 1988;34(3):178-84. doi: 10.1159/000238568.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验